

Table 1. Clinical, laboratory characteristics of patients with different levels of IKZF1 Δ 2-8/ALB deletions

Variant	Total (n=74)	IKZF1/ALB < 1% (n=45)	IKZF1/ALB \geq 1% (n=29)	P
Male (%)	46(62.2%)	25(55.6%)	21(72.4%)	0.144
Female (%)	28(37.8%)	20(44.4%)	8(27.6%)	
Median age (years)(range)	8(1-17)	6(1-16)	11(1-17)	0.031
1 to 10 yeas (%)	41(55.4%)	28(62.2%)	13(44.8%)	0.142
\geq 10 yeas (%)	33(44.6%)	17(37.8%)	16(55.2%)	
WBC count ($\times 10^9$ /L) (%)				0.031
<50	58 (78.4%)	39(86.7%)	19(65.5%)	
\geq 50	16(21.6%)	6(13.3%)	10(34.5%)	
LDH (U/L)	545.0 \pm 479.5	515.8 \pm 437.7	519.0 \pm 544.0	0.520
UA (umol/L)	370.3 \pm 138.6	348.7 \pm 108.2	404.2 \pm 173.0	0.137
Immunologic subtype (%)				0.405
Com-B-ALL	68(91.9%)	41(91.1%)	27(93.1%)	
Pre-B-ALL	3(4.05%)	1(2.2%)	2(6.9%)	
Pro-B-ALL	3(4.05%)	3(6.7%)	0(0%)	
Fusion transcripts (%)				0.01
BCR-ABL1	10(13.5%)	1(2.2%)	9(31.0%)	
E2A/PBX1	1(1.4%)	1(2.2%)	0(0%)	
ETV6/RUNX1	8(10.8%)	8(17.8%)	0(0%)	
Other	55(74.3%)	35(77.8%)	20(69.0%)	
Karyotype (%)				0.501
Hyperdiploid	11(14.9%)	8(17.8%)	3(10.3%)	
Hypodiploid	11(14.9%)	8(17.8%)	3(10.3%)	
Normal	29(39.2%)	15(33.3%)	14(48.3%)	
Other	23(31.0%)	14(31.1%)	9(31.1%)	
MRD on 15 days (%)				0.686
MRD \geq 5%	26(35.1%)	15(33.3%)	11(37.9%)	
MRD <5%	48(64.9%)	30(66.7%)	18(62.1%)	
MRD on 33 days (%)				0.797
MRD < 0.01%	43(58.1%)	27(60.0%)	16(55.2%)	
0.01% \leq MRD < 1%	23(31.1%)	14(31.1%)	9(31.0%)	
MRD \geq 1%	8(10.8%)	4(8.9%)	4(13.8%)	
Risk stratification (%)				0.001
IR	53(71.6%)	39 (86.7%)	14(48.3%)	
HR	21(28.4%)	6(13.3%)	15(51.7%)	
CNSL (%)				0.126
Yes	14(18.9%)	6(13.3%)	8(27.6%)	
No	60(81.1%)	39(86.7%)	21(72.4%)	
TKI (%)				<0.001
Yes	27(36.5%)	7(15.6%)	20(69.0%)	

No	47(63.5%)	38(84.4%)	9(31.0%)	
HSCT (%)				
Yes	14(18.9%)	5(11.1%)	9(31.0%)	0.033
No	60(81.1%)	40(88.9%)	20(69.0%)	
Relapse/Refractory (%)				
Yes	16(21.6%)	6(13.3%)	10(34.5%)	0.031
No	58(78.4%)	39(86.7%)	19(65.5%)	
Death (%)				
Yes	6(8.1%)	1(2.2%)	5(17.2%)	0.020
No	68(91.9%)	44(97.8%)	24(82.8%)	

Abbreviations: LDH, lactate dehydrogenase. UA, uricacid. CNSL, central nervous system leukemia. TKI, tyrosine kinase inhibitor. HSCT, hematopoietic stem cell transplantation.